These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 31522467)

  • 1. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation.
    Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K
    Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABO-incompatible pediatric kidney transplantation without antibody removal.
    Kawamura T; Hamasaki Y; Takahashi Y; Hashimoto J; Kubota M; Muramatu M; Itabashi Y; Hyodo Y; Ohashi Y; Aikawa A; Sakai K; Shishido S
    Pediatr Nephrol; 2020 Jan; 35(1):95-102. PubMed ID: 31673829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological Analysis in ABO-Compatible and ABO-Incompatible Kidney Transplantation by Performance of 3- and 12-Month Protocol Biopsies.
    Masutani K; Tsuchimoto A; Kurihara K; Okabe Y; Kitada H; Okumi M; Tanabe K; Nakamura M; Kitazono T; Tsuruya K;
    Transplantation; 2017 Jun; 101(6):1416-1422. PubMed ID: 27391195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
    Sugiyama K; Hyodo Y; Aikawa A
    Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the prevalence of systemic de novo thrombotic microangiopathy after ABO-incompatible kidney transplantation and the associated risk factors.
    Tasaki M; Saito K; Nakagawa Y; Imai N; Ito Y; Yoshida Y; Ikeda M; Ishikawa S; Narita I; Takahashi K; Tomita Y
    Int J Urol; 2019 Dec; 26(12):1128-1137. PubMed ID: 31587389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
    Han S; Hwang E; Park S; Park U; Kim H; Cho W
    Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
    Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
    PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABO-incompatible living donor kidney transplantation without post-transplant therapeutic plasma exchange.
    Yabu JM; Fontaine MJ
    J Clin Apher; 2015 Dec; 30(6):340-6. PubMed ID: 25739580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.
    Sawada T; Fuchinoue S; Teraoka S
    Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
    Opelz G; Morath C; Süsal C; Tran TH; Zeier M; Döhler B
    Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
    Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
    Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of ABO-Incompatible Living Donor Renal Transplantations: A Single-Center Experience From Eastern India.
    Ray DS; Thukral S
    Transplant Proc; 2016 Oct; 48(8):2622-2628. PubMed ID: 27788792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Desensitization with the Use of an Antibody Removal-Free Protocol in ABO-Incompatible Kidney Transplant Recipients with a Low Anti-A/B Antibody Titer.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018 May; 50(4):982-986. PubMed ID: 29731097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative rebound of antiblood type antibodies and antibody-mediated rejection after ABO-incompatible living-related kidney transplantation.
    Ishida H; Kondo T; Shimizu T; Nozaki T; Tanabe K
    Transpl Int; 2015 Mar; 28(3):286-96. PubMed ID: 25363583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
    Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
    Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
    Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
    Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic apheresis in ABO-incompatible kidney and liver transplantation: A single-center experience of 50 patients.
    Pandey P; Setya D; Sinha V; Bhatt A; Devra A; Chaudhary A; Ranjan S; Srivastava R; Kumar P; Singh MK
    Ther Apher Dial; 2021 Feb; 25(1):103-117. PubMed ID: 32266793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
    Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
    Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.